Artikel New Bioreactor Produces Millions of Immune Cells Weekly pertama kali tampil pada todayinasian.com.
]]>Macrophages are one of the immune system’s most essential defenders. Often called the body’s “scavenger cells,” they hunt down pathogens, clear away cellular debris, and help repair damaged tissue. Their medical potential extends even further, with scientists exploring their use in treating liver disease, infections, cancer, fibrosis, and neurodegenerative conditions such as Alzheimer’s. The challenge has never been their usefulness; it has been making enough of them.
The new system begins with induced pluripotent stem cells, or iPSCs—adult cells reprogrammed to return to a flexible, embryonic-like state. These cells can become virtually any cell type in the human body, making them a cornerstone of modern biotechnology. Inside the bioreactor, the iPSCs develop into organoid-like structures that mimic human bone marrow, effectively creating a miniature immune-cell factory. After roughly two weeks, these structures begin continuously releasing macrophages.
Read More: Quantum Dots Send Unhackable Keys Over 120 km Fiber
Professor Nico Lachmann, who led the research, described the system’s impressive output: “We can harvest up to 40 million immune cells per bioreactor every week over a period of 10 weeks.” That kind of consistency is a game-changer, especially for preclinical studies where researchers need large, reliable batches of human cells.
Unlike small laboratory cultures or massive industrial systems, this medium-scale platform hits a sweet spot. It is efficient, cost-effective, and manageable, making it particularly attractive for research institutions and biotech developers. Four bioreactors can even operate together in a single device, boosting productivity without adding excessive complexity. Think of it as the “just right” bowl of porridge in cell manufacturing—Goldilocks would approve.
The implications are enormous. With a dependable supply of macrophages, scientists can better test new drugs, model diseases, and refine cell-based therapies. It also brings the field closer to scalable treatments that could one day be produced on demand.
Viewed through a broader lens, this innovation is more than a laboratory upgrade. It represents a shift from handcrafted biology to precision manufacturing, where living cells can be cultivated with the consistency of modern engineering—and perhaps one day, delivered with equal reliability.
Artikel New Bioreactor Produces Millions of Immune Cells Weekly pertama kali tampil pada todayinasian.com.
]]>Artikel Samsung Medical Center Sets Pace for AI Smart Hospitals pertama kali tampil pada todayinasian.com.
]]>Yet this achievement is not merely about maintaining status—it is about deepening purpose. Over the past few years, the medical center has shifted its focus from simply deploying advanced technologies to fully integrating them into daily clinical operations. The transformation is subtle but powerful, like turning tools into instincts. Its infrastructure now supports large-scale data processing, enabling clinicians to make faster, more informed decisions based on real-time insights.
One of the most striking upgrades lies in the hospital’s data center transformation. Executed on what experts described as an “unprecedented scale,” the relocation of its Internet Data Centre was completed with only about 20 minutes of downtime—an almost poetic feat in a setting where every second matters. The result is a system that reduces latency by roughly 50%, allowing complex, GPU-driven artificial intelligence workloads to operate more efficiently.
Read More: Glass Chip Breakthrough Boosts Quantum Data Security
Dr Kyu-Sung Lee, chief data and digital officer, captured the spirit of this evolution, explaining that the expanded infrastructure now forms “the foundation for large-scale clinical data processing and data-driven operational management.” He added that use cases involving high-volume data, such as patient-centered imaging exchange, are especially poised to benefit from these advancements. His words feel less like a technical report and more like a glimpse into a future where information moves as seamlessly as care itself.
Behind the scenes, the hospital’s systems continuously collect and analyze vast streams of operational data—from performance metrics to user activity—creating a living ecosystem that learns, adapts, and improves. This capacity allows healthcare providers to anticipate needs, refine workflows, and elevate patient outcomes with quiet precision.
Seen from a broader perspective, Samsung Medical Center’s journey reflects a turning point in global healthcare, where hospitals are no longer just places of treatment but intelligent environments that think, respond, and evolve. It is a vision where technology does not replace human touch, but gently amplifies it—turning complexity into clarity, and data into something almost humane.
Artikel Samsung Medical Center Sets Pace for AI Smart Hospitals pertama kali tampil pada todayinasian.com.
]]>Artikel China’s Surgical Robot Speeds Brain Imaging by 29% pertama kali tampil pada todayinasian.com.
]]>The system, known as a cerebrovascular intervention robot, was tested at Peking Union Medical College Hospital, where a young surgeon used it to complete a standard procedure nine minutes faster than conventional techniques. In measurable terms, what once took around 38 minutes was reduced to just 27, a difference that may seem small on paper but carries weight in the delicate choreography of brain care.
Lead researcher Dr Zhao Yuanli described the early findings with cautious optimism, noting, “the YDHB-NS01 robot-assisted system is feasible for diagnostic cerebral angiography,” and that it shows “early indications of safety and comparable procedural performance” to manual methods. His words echo a tone familiar in scientific progress—hope wrapped in restraint, discovery tempered by verification.
Read More: Harvard Chip Breakthrough Can Twist Light in Real Time
Behind this innovation lies a deeper problem the robot seeks to ease. Brain imaging procedures require threading a thin wire from the thigh to the brain’s blood vessels under continuous X-ray guidance, a task demanding unwavering steadiness. Human hands, however skilled, are not immune to tremors, fatigue, or the burden of heavy radiation-protection gear. Over time, even the healers carry risk.
The robotic system offers a different kind of touch—steady, tireless, and shielded from radiation. Early trials involving dozens of patients reported a 100 percent success rate in both robotic and manual groups, with no complications observed, suggesting that speed does not come at the cost of safety.
Seen from a wider lens, this development is less about machines replacing humans and more about extending human capability. The study itself remains limited in scale, and researchers acknowledge the need for broader trials, but the direction is clear: a future where precision is augmented, risk is softened, and time—so often the quiet enemy in medicine—is gently reclaimed.
Artikel China’s Surgical Robot Speeds Brain Imaging by 29% pertama kali tampil pada todayinasian.com.
]]>Artikel China’s Neuracle Brain Chip Gets Approval for Human Use pertama kali tampil pada todayinasian.com.
]]>Brain-computer interfaces, commonly known as BCIs, are systems that translate neural signals from the brain into commands that computers or machines can interpret. In simple terms, they allow a person to control external devices using thoughts alone. The implantable system developed by Neuracle involves electrodes placed inside the brain to capture neural activity, which is then decoded by software to operate digital tools or assistive equipment. Researchers believe such devices could transform the lives of patients with paralysis or severe neurological injuries.
The newly approved technology represents one of the most advanced forms of BCI, classified as an invasive interface because it requires surgical implantation. While this approach involves greater medical complexity than non-invasive systems that sit outside the skull, it offers much clearer brain signals and more precise control over connected devices. Clinical experiments conducted in China have already demonstrated that implanted patients can use the technology to perform tasks such as controlling computers or interacting with digital environments.
Read More: Silicone Wristbands: The New Tool to Track Forever Chemical Exposure
Neuracle, founded in 2011, has spent years refining the implantable system in partnership with research institutions and hospitals. Earlier trials reportedly involved patients who regained the ability to interact with computers after the device captured neural signals from the brain’s motor regions. One medical specialist involved in the research reportedly said the results were “better than we expected,” highlighting the rapid progress being made in the field.
China’s growing support for brain-computer interface technology reflects a broader national strategy to develop cutting-edge industries that combine neuroscience, artificial intelligence, and advanced electronics. Government policies released in recent years have placed BCIs among the country’s “future industries,” encouraging research breakthroughs and clinical applications that could reshape healthcare and human-machine interaction.
Looked at from a wider perspective, the approval of Neuracle’s implantable brain chip suggests that BCIs are steadily moving from laboratory experiments toward real-world medical treatments. As scientists refine the technology and expand clinical trials, devices that translate thoughts into digital actions may soon become an important tool in restoring independence and quality of life for patients living with severe neurological conditions.
Artikel China’s Neuracle Brain Chip Gets Approval for Human Use pertama kali tampil pada todayinasian.com.
]]>Artikel Silicone Wristbands: The New Tool to Track Forever Chemical Exposure pertama kali tampil pada todayinasian.com.
]]>PFAS — perfluoroalkyl and polyfluoroalkyl substances — are widely known as “forever chemicals” because of how extraordinarily long they persist in the environment without breaking down. Tracking exposure to these substances has long been a challenge for researchers. Traditional methods such as blood draws are not only costly but can discourage people from participating in studies altogether.
Conventional environmental monitoring has largely relied on snapshots — a water sample collected on a single day, a blood draw at one moment in time — but exposure is not a single moment. It unfolds gradually as people move through different environments, touching surfaces, breathing air, and interacting with everyday products. That gap in understanding is what pushed researchers toward passive, noninvasive monitoring tools.
Read More: Dolphin-Shaped Robot Could Revolutionize Ocean Oil Spill Cleanup
Silicone wristbands are made of polydimethylsiloxane (PDMS), a polymer with a strong capacity for absorbing a wide range of organic chemicals. As the band sits on the wrist, compounds from air, dust, and nearby surfaces slowly diffuse into the silicone material. After days or weeks of wear, scientists can extract and analyze those compounds to map out a person’s exposure patterns.
Researchers have already applied this approach in community studies involving adolescent girls in agricultural areas, firefighters, and office workers — groups with potentially high but underexplored chemical exposures.
The wristbands have also been adapted for wildlife research, helping scientists assess chemical accumulation in animals without causing them physical stress.
Moving at even a walking pace can enhance a wristband’s chemical uptake rate by as much as 3.2 times, making everyday movement itself a factor in the quality of data collected.
It is a remarkable intersection of ordinary life and cutting-edge environmental science — proof that sometimes the most powerful research tools are the ones people are willing to actually wear.
Artikel Silicone Wristbands: The New Tool to Track Forever Chemical Exposure pertama kali tampil pada todayinasian.com.
]]>Artikel Microrobots Swim Inside Blood Vessels to Deliver Stroke Drugs pertama kali tampil pada todayinasian.com.
]]>The microrobot is structured around a spherical gel capsule that holds the therapeutic compound. Embedded in this gel are iron-oxide nanoparticles, which respond to externally applied magnetic fields. This design makes the capsule controllable even in fast-flowing blood, enabling it to reach regions deep in the brain’s vascular network. Once at its destination, a high-frequency magnetic field heats the nanoparticles, causing the gel shell to dissolve and release the drug precisely where it is needed.
To navigate complex vessel architectures, the team developed a three-strategy magnetic steering system. One mode uses a rotating magnetic field to roll the capsule along vessel walls, another applies a magnetic-gradient pull that lets the microrobot move even against blood flow, and a third method steers it through branch points by directing the field against the vessel wall. In head artery conditions, the robot can travel at speeds up to 4 millimetres per second — a notable achievement given the strong currents and confined spaces.
Read More: Robots That Cook: AI and Automation Enter the Kitchen
The researchers further included tantalum nanoparticles to make the microrobot visible under X-ray imaging, which enables real-time tracking during its journey. This feature helps clinicians monitor and confirm where the drug payload is delivered, boosting both the safety and effectiveness of the therapy.
In animal trials, the microrobots have been successfully deployed through realistic vessel models as well as in large-animal testing: ETH Zurich confirmed they worked reliably in pigs’ vessels and even within the cerebrospinal fluid of sheep. These tests showed that the system could reliably steer, release medication and dissolve without causing damage.
The innovation has particular implications for stroke treatment. Traditional therapies often require high systemic doses of clot-dissolving drugs, which carry risk of side effects like internal bleeding. By delivering medication only to the clot site, the microrobots promise to reduce side effects significantly while maintaining efficacy.
Artikel Microrobots Swim Inside Blood Vessels to Deliver Stroke Drugs pertama kali tampil pada todayinasian.com.
]]>Artikel Soft-Vine Robot Slithers Through Arteries and Jet Engines pertama kali tampil pada todayinasian.com.
]]>The core innovation involves integrating a thin robotic skin embedded with actuators composed of liquid-crystal elastomer (LCE). This skin is wrapped around a soft body that everts turns inside-out at the tip allowing the robot to extend forward without dragging against surrounding surfaces. By controlling internal pressure and selectively heating the LCE actuators, the robot can both stiffen and bend, enabling it to twist through tight curves and squeeze into gaps as narrow as half its own diameter.
In laboratory demonstrations, machines between 3 and 7 millimetres in diameter and about 25 centimetres in length managed turns exceeding 100 degrees, traversed a model of a human aorta, and threaded into the interior of a jet-engine mock-up. One researcher said the advance “represents a step toward small, steerable, soft vine robots for applications in delicate and constrained environments.”
Read More: Tiny Robot Muscle Lifts 4,000× Its Weight with Soft-to-Steel Switch
Traditional soft-robot designs often struggle with steering at such small scales because actuators and mechanisms become bulky relative to the body. The UCSD team overcame this by using the ultra-thin LCE layer and heaters embedded beneath it, so the robot can change curvature by activating temperature zones while pressure maintains shape. They found that using pressure control and heater actuation together provided superior steering precision and responsiveness.
The researchers envision a wide range of applications: in medicine, the vine robot could navigate vascular systems for minimally invasive diagnostics or treatment; in aerospace or industrial inspection, it could venture into confined cavities or tight engine passages inaccessible to conventional tools. They noted that this skin technique could also be adapted for soft grippers, wearable haptic devices, or mobile limbs in future robot systems.
While the prototype is promising, scaling it for real-world deployment still involves challenges. Mapping human anatomical variation, ensuring robustness under long-term use, and developing reliable autonomous control are next steps. But the work highlights a significant leap: robots not just stiff or rigid, but able to behave like flexible vines—growing, steering, and adapting to the environment in real time.
Artikel Soft-Vine Robot Slithers Through Arteries and Jet Engines pertama kali tampil pada todayinasian.com.
]]>Artikel Doximity Buys Pathway Medical in $63M Healthcare AI Deal pertama kali tampil pada todayinasian.com.
]]>Founded with a mission to democratize high-quality medical knowledge, Pathway leverages machine learning to help clinicians quickly access relevant clinical guidelines and research, aiming to speed up evidence-based decision-making in practice. The platform already supports healthcare professionals across more than 180 countries and 30+ specialties.
By integrating Pathway’s robust AI reference platform, Doximity is poised to deepen its existing offerings—such as secure messaging, telehealth services, scheduling tools, and the popular Doximity newsfeed—with advanced decision support features. Pathway’s technology can help fill gaps in clinician workflows by providing instant, accurate guidance through an ever-growing body of medical knowledge.
Read More: Meet Xueba 01: The First Robot to Pursue a PhD in Theatre
This move also underscores a broader trend of consolidation in clinical AI, where established digital health companies bolster their product suites through strategic acquisitions. For Doximity, which has seen strong financial performance in recent years—as showcased by rising revenues and active clinician engagement across its suite—this acquisition sharpens its competitive edge.
However, it’s worth noting that both Doximity and Pathway are currently involved in legal controversy. In a federal lawsuit filed by OpenEvidence, both companies stand accused of engaging in “prompt injection” attacks—attempts to extract proprietary AI system prompts—from OpenEvidence’s AI platform, raising serious concerns about intellectual property and trade secret protections in AI development.
As Doximity integrates Pathway’s reference platform into its ecosystem, key questions arise: How will the acquisition affect clinician workflow efficiency and quality of care? Can the company navigate the legal challenges surrounding prompt injection ethically and responsibly? And will the combined capabilities solidify Doximity’s role as an indispensable AI partner to healthcare professionals?
Going forward, stakeholders will watch how Doximity leverages Pathway’s tools while ensuring legal clarity and maintaining trust in clinical AI applications—especially vital in a sector where accuracy and confidentiality materially impact patient outcomes.
Artikel Doximity Buys Pathway Medical in $63M Healthcare AI Deal pertama kali tampil pada todayinasian.com.
]]>